Since our analysis suggests that SUMO2 specific conjugation of certain proteins putatively occurs in GBM, pull-down assays in combination with mass spectrometry may enable the identification of such SUMOylated tumour-specific biomarkers in exosomes. This evidence concerns the gene SUMO2 and neoplasm.